Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

MED


Top 10 Correlated ETFs

MED


Top 10 Correlated Stocks

MED


In the News

09:23 25 Sep 2022 MED

My Top 10 Dividend Payers For September

Dividends are an important source of income for investors of all types but especially those that rely on their investments in retirement. My ideal dividend payer accomplishes four goals: maximize total return, deliver a meaningful yield, experience strong growth, and provide a margin of safety.

04:14 25 Sep 2022 MED

7 Dividend Stocks to Buy and Hold Forever

If you're looking for dividend stocks to buy and hold forever, a good place to start is companies that have done an excellent job increasing their dividends and are expected to keep doing so in the future.  While the first place to look for such names should logically be a list of S&P 500 Dividend Aristocrats, I widened the search to the S&P 1500.

09:03 25 Sep 2022 MED

Losing Weight Is Losing Ground in the Stock Market

Weight-loss and nutrition companies have lost half or more of their value in the past year despite expectations of a postpandemic boom.

03:09 25 Sep 2022 MED

Medifast: Would Chuck Akre Approve?

It is a consistently profitable growth company that was recognized by Fortune and Forbes several times. Yet, the stock has crashed over 64% since it peaked on 1st May 2021, falling from $332.25 to $119.05 as of 2 September 2022.

09:47 25 Sep 2022 MED

Medifast (MED) Down More Than 20% in 3 Months on Cost Woes

Medifast (MED) has been seeing high SG&A expenses and escalated raw material costs. The company expects short-term margin pressure in 2022 due to inflation and continued investments.

01:26 25 Sep 2022 MED

Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good

Medifast's stock plummeted 16% after reporting Q2 earnings. Both earnings and revenue beat analysts' consensus but guidance was cut significantly.

02:18 25 Sep 2022 MED

Medifast (MED) Q2 Earnings Top Estimates, Guidance Lowered

Medifast's (MED) second-quarter 2022 results reflect increased active earning OPTAVIA Coaches and elevated costs. Management cuts guidance for 2022 due to inflation.

11:27 25 Sep 2022 MED

Medifast, Inc. (MED) CEO Dan Chard on Q2 2022 Results - Earnings Call Transcript

Medifast, Inc. (NYSE:MED ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Reed Anderson - ICR, Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Chris Neamonitis - Jefferies Operator Good afternoon. And welcome to Medifast Second Quarter 2022 Earnings Conference Call.

09:16 25 Sep 2022 MED

Explore DuPont Analysis & Pick 5 Top Stocks

Do you have more faith in DuPont analysis than simple ROE calculation? Tap UFP Industries (UFPI), MEDIFAST (MED), Skyline (SKY), Hudson Global (HSON) and Expeditors International of Washington (EXPD).

06:39 25 Sep 2022 MED

Dive Into DuPont Analysis & Pick 5 Top Stocks

Do you have more faith in DuPont analysis than simple ROE calculation? Tap Sanderson Farms (SAFM), MEDIFAST (MED), Skyline (SKY), Hudson Global (HSON) and Expeditors International of Washington (EXPD).

Financial details

Company Rating
Strong Buy
Market Cap
1.31B
Income
156.9M
Revenue
1.66B
Book val./share
11.4
Cash/share
5.38
Dividend
6.34
Dividend %
5.64%
Employees
984
Optionable
No
Shortable
Yes
Earnings
02 Nov 2022
P/E
8.34
Forward P/E
8.71
PEG
1.51
P/S
0.77
P/B
9.86
P/C
20.89
P/FCF
18.79
Quick Ratio
0.32
Current Ratio
1.29
Debt / Equity
0.18
LT Debt / Equity
0.18
-
-
EPS (TTM)
13.56
EPS next Y
12.9
EPS next Q
2.51
EPS this Y
60.52%
EPS next Y
-4.87%
EPS next 5Y
-4.87%
EPS last 5Y
43.32%
Revenue last 5Y
38.31%
Revenue Q/Q
8.56%
EPS Q/Q
-4.97%
-
-
-
-
SMA20
-13.53%
SMA50
-33.72%
SMA100
-35.09%
Inst Own
82.17%
Inst Trans
-1.39%
ROA
46%
ROE
84%
ROC
1.35%
Gross Margin
73%
Oper. Margin
12%
Profit Margin
9%
Payout
46%
Shs Outstand
11.02M
Shs Float
9.99M
-
-
-
-
Target Price
-
52W Range
116.5-235.71
52W High
-52.17%
52W Low
-3.11%
RSI
28
Rel Volume
0.6
Avg Volume
190.01K
Volume
114.22K
Perf Week
-6.99%
Perf Month
-14.87%
Perf Quarter
-36.27%
Perf Half Y
-35.85%
-
-
-
-
Beta
1.19297
-
-
Volatility
2.92%, 8.97%
Prev Close
-1.77%
Price
112.39
Change
-1.78%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
25.2941.9460.6379.42130.52
Net income per share
2.324.676.628.7414.03
Operating cash flow per share
3.635.097.1612.348.09
Free cash flow per share
3.354.686.311.835.16
Cash per share
8.298.467.8714.829.37
Book value per share
9.119.138.9113.3617.32
Tangible book value per share
9.119.138.9113.3617.32
Share holders equity per share
9.119.138.9113.3617.32
Interest debt per share
0000.172.78
Market cap
837.18M1.49B1.16B2.76B2.24B
Enterprise value
762.11M1.41B1.08B2.6B2.17B
P/E ratio
30.226.7814.8426.8613.67
Price to sales ratio
2.782.981.622.951.47
POCF ratio
19.3624.5713.7319.0223.71
PFCF ratio
20.9326.7415.5919.8337.16
P/B Ratio
7.7113.6911.0317.5711.07
PTB ratio
7.7113.6911.0317.5711.07
EV to sales
2.532.821.512.781.42
Enterprise value over EBITDA
17.1118.8411.1318.379.73
EV to operating cash flow
17.6323.2312.8117.9122.96
EV to free cash flow
19.0625.2814.5518.6735.97
Earnings yield
0.030.040.070.040.07
Free cash flow yield
0.050.040.060.050.03
Debt to equity
00000.13
Debt to assets
0.260.360.460.430.49
Net debt to EBITDA
-1.69-1.09-0.79-1.14-0.32
Current ratio
3.372.411.942.11.81
Interest coverage
00000
Income quality
1.561.091.081.410.58
Dividend Yield
0.020.020.030.020.03
Payout ratio
0.560.420.450.520.39
Sales general and administrative to revenue
0000.60
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
-0.07-0.08-0.12-0.04-0.36
Capex to revenue
-0.01-0.01-0.01-0.01-0.02
Capex to depreciation
-0.77-1.11-2.18-0.81-5.02
Stock based compensation to revenue
0.010.010.010.010.01
Graham number
21.8230.9836.4251.2573.93
ROIC
0.360.630.790.810.95
Return on tangible assets
0.190.330.40.370.41
Graham Net
65.12.417.030.32
Working capital
88.06M85.2M74.76M122.96M137.03M
Tangible asset value
00000
Net current asset value
87.85M85.2M64.33M115.48M111.01M
Invested capital
0000.010.16
Average receivables
580K797.5K1.01M584K0
Average payables
25.96M28.79M29.19M35.77M53.33M
Average inventory
36.36M46.14M51.08M53.39M116.72M
Days sales outstanding
0.70.740.730.230
Days payables outstanding
79.9265.7546.6755.0864.94
Days of inventory on hand
95.66117.21100.6882.22164.91
Receivables turnover
523.55495.55496.641.6K0
Payables turnover
4.575.557.826.635.62
Inventory turnover
3.823.113.634.442.21
ROE
0.260.510.740.650.81
Capex per share
-0.27-0.41-0.85-0.5-2.93

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
33.5435.3632.3236.1339.93
Net income per share
43.592.913.623.44
Operating cash flow per share
1.781.35-0.643.783.85
Free cash flow per share
1.130.46-1.633.523.6
Cash per share
16.813.689.3710.565.38
Book value per share
16.5716.7817.3218.6911.4
Tangible book value per share
16.5716.7817.3218.6911.4
Share holders equity per share
16.5716.7817.3218.6911.4
Interest debt per share
1.751.682.782.684.97
Market cap
3.33B2.25B2.45B1.97B2.05B
Enterprise value
3.15B2.12B2.38B1.89B2.04B
P/E ratio
17.713.4117.9911.8113.1
Price to sales ratio
8.445.456.484.734.52
POCF ratio
159.3142.55-328.2845.1946.83
PFCF ratio
250.44416.25-128.3248.5450.08
P/B Ratio
17.0811.4812.099.1415.83
PTB ratio
17.0811.4812.099.1415.83
EV to sales
85.126.294.524.51
Enterprise value over EBITDA
49.3136.6251.3532.9139.56
EV to operating cash flow
151.09134.02-318.6843.246.72
EV to free cash flow
237.53391.32-124.5646.449.97
Earnings yield
0.010.020.010.020.02
Free cash flow yield
00-0.010.020.02
Debt to equity
0.080.070.130.110.18
Debt to assets
0.470.470.490.490.62
Net debt to EBITDA
-2.68-2.33-1.55-1.52-0.09
Current ratio
1.981.871.811.791.29
Interest coverage
000-579.86298.56
Income quality
0.440.38-0.221.051.12
Dividend Yield
0.010.010.010.010.01
Payout ratio
0.360.40.50.40.48
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
-0.36-0.661.56-0.07-0.06
Capex to revenue
-0.02-0.03-0.03-0.01-0.01
Capex to depreciation
-2.89-3.9425.11-1.23-1.04
Stock based compensation to revenue
0.010.010.010.010.01
Graham number
38.5936.8233.6738.9929.73
ROIC
0.290.260.20.230.32
Return on tangible assets
0.130.110.090.10.11
Graham Net
6.454.240.320.96-6.3
Working capital
150.34M140.14M137.03M143.23M55.14M
Tangible asset value
00000
Net current asset value
134.78M125.92M111.01M118.85M32.23M
Invested capital
0.110.10.160.140.43
Average receivables
00000
Average payables
00000
Average inventory
142.38M159.29M184.51M188.97M172.97M
Days sales outstanding
00000
Days payables outstanding
0064.090105.81
Days of inventory on hand
85.8109.7162.77147.49107.31
Receivables turnover
00000
Payables turnover
001.400.85
Inventory turnover
1.050.820.550.610.84
ROE
0.240.210.170.190.3
Capex per share
-0.65-0.89-0.99-0.26-0.25

Frequently Asked Questions

What is Medifast, Inc. stock symbol ?

Medifast, Inc. is a US stock , located in Owings mills of Maryland and trading under the symbol MED

What is Medifast, Inc. stock quote today ?

Medifast, Inc. stock price is $112.39 today.

Is Medifast, Inc. stock public?

Yes, Medifast, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap